Improving treatment for deadly brain tumors
Study finds ChemoID platform-predicted treatments lead to longer survival
New multi-institutional phase 3 clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.
The University of Cincinnati’s Soma Sengupta, MD, PhD, a co-first author of the research and a University of Cincinnati Cancer Center physician-researcher, said the research focused on patients whose glioblastoma had returned after initial treatment.
The trial tested the effectiveness of a platform called ChemoID, a CLIA and CAP-accredited diagnostic test, developed by Dr. Pier Paolo Claudio and Dr. Jagan Valluri of Cordgenics LLC.
“ChemoID looks at cancer stem cells and their sensitivity to specified drugs to see which ones will work in a given cancer setting,” said Sengupta, UC associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist, funded by the Harold C. Schott Endowed Chair in Molecular Therapeutics (Neurosurgery) and the Pam and Tom Mischell Funds.
Soma Sengupta, MD, PhD. Photo/UC Health.
Patients in the trial were randomized to have the choice of chemotherapy treatment decided through ChemoID or to have physicians choose the chemotherapy using standard methods. Sengupta noted oncologists choosing treatments are often dictated by guidelines and insurance considerations.
Those who had their treatments selected through ChemoID had a significantly lower risk of death and, on average, survived 3.5 months longer than those in the physician-choice group.
“We were pleasantly surprised that the ChemoID group did better and that a cancer stem cell-derived test is important in this disease,” Sengupta said. “Where survival in recurrent glioblastoma is extremely poor, 3.5 months or more is wonderful. Some of my patients on this trial are still alive.”
Claudio explained that because ChemoID focuses on choosing treatments using commercially available chemotherapies, this approach offers a way for patients to receive more effective treatment at a lower cost.
Sengupta said the team plans to apply for funding through the National Institutes of Health to develop ChemoID further. A modified platform could expand to include immunotherapy treatments or targeted therapies.
According to Valluri, if the anti-cancer therapy that targets cancer stem cells is incorporated earlier in the treatment plan, ineffective treatments will be eliminated, and patients will be able to receive the maximum therapeutic benefit.
“This is an example of a highly collaborative project,” Sengupta said. “At UC alone, several colleagues, including Dr. Mario Zuccarello and Dr. Rekha Chaudhary, were involved.”
Featured photo at top of a CT brain scan. Photo/Tonpor Kasa/iStock.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
UC Foundation Board of Trustees announces seven new members
June 17, 2026
The University of Cincinnati Foundation is proud to announce that seven dedicated community members are joining its board of trustees. Ray Brooks, CEAS ’83; Chris Carper, A&S ’93; Tim Giglio, Bus ’84; Nandita Jena, A&S '03, Bus '03 and Chris Lewis, MD, Med ’00 will begin their term in October 2026. In addition to this esteemed group, two new student trustees, Case Trokhan, Med ’26 and Joseph Verry, Med ’30 are joining the board.
Rivers expert says satellite technology can help protect drinking water
June 17, 2026
University of Cincinnati environmental engineering professor Dongmei Feng is using satellite remote sensing to study rivers around the world and protect drinking water supplies. As co-lead author of a paper in Nature Water and the recipient of two major federal grants, Feng is developing tools to monitor nutrient pollution and toxic algal blooms from space, with applications for cities like Cincinnati.
Aerospace engineering professor named ASME Fellow
June 16, 2026
Prashant Khare, professor of aerospace engineering at the University of Cincinnati and prolific researcher in the field of fluid dynamics, added another accolade to his list of achievements. Earlier this year, he was named a Fellow of the American Society of Mechanical Engineers, an honor bestowed on only 5% of all members of the organization. He serves as head of the Department of Aerospace Engineering and Engineering Mechanics at the College of Engineering and Applied Science.